Skip to content
Screener

Regenxbio RGNX Q3 2025 earnings

Reported November 6, 2025 · Before market open

Revenue$29.7MMiss by $29.5M
EPS-$1.20Beat by $0.18
Revenue estimate$59.3M
EPS estimate-$1.38

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$15.9M
EPS estimate-$1.21

Financials

Q3 2025

Income statement

See full
Revenue$29.7M+22.9%
Operating income-$52.4M+15.6%
Net income-$61.9M-3.9%
EPS (diluted)-$1.20-2.6%

Balance sheet

See full
Cash & equivalents$58.8M+3.9%
Total debt$76.5M-9.0%
Total equity$161.5M-46.4%
Total assets$525.2M+1.2%

Cash flow

See full
Operating cash flow-$56.0M-38.0%
CapEx$491.0K+50.6%
Free cash flow-$56.5M-38.1%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$487.46M-8.2%
Enterprise value$505.17M-9.5%
P/S3×-3.3×

Profitability

See full
Operating margin-96%-38.6pp
Net margin-110.3%-41.8pp
FCF margin-65.9%-27.1pp

Returns & leverage

See full
Return on equity-76.9%+5.7pp
Debt / equity0.5×+0.2×
Current ratio2.7×-0.4×

Segments

By product

See full
Nippon Shinyaku Services$5.9M—
Other Service Revenue$196.0K-8.8%

FAQ

When did Regenxbio report Q3 2025 earnings?
Regenxbio (RGNX) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Regenxbio's Q3 2025 revenue and EPS?
Regenxbio reported revenue of $29.7M and eps of $-1.20 for Q3 2025.
Did Regenxbio beat estimates in Q3 2025?
Revenue missed the consensus estimate of $59.3M by $29.5M. EPS beat the consensus estimate of $-1.38 by $0.18.
How did Regenxbio's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 22.9% from $24.2M a year earlier and eps declined 2.6% from $-1.17.
Where can I find Regenxbio's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-268101) and the 10-Q periodic report (0001193125-25-268095) directly on SEC EDGAR. The filing index links above go to sec.gov.